Phreesia, Inc. (NYSE:PHR) COO Evan Roberts Sells 2,873 Shares

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 2,873 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $76,450.53. Following the completion of the sale, the chief operating officer now owns 779,993 shares of the company’s stock, valued at approximately $20,755,613.73. The trade was a 0.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Evan Roberts also recently made the following trade(s):

• On Tuesday, October 15th, Evan Roberts sold 1,843 shares of Phreesia stock. The shares were sold at an average price of $21.03, for a total value of $38,758.29.

Phreesia Trading Up 5.3 %

PHR opened at $28.42 on Friday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $22.70 and a 200-day simple moving average of $22.57. The firm has a market cap of $1.65 billion, a P/E ratio of -19.33 and a beta of 0.94.

Phreesia (NYSE:PHR) last released its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. Phreesia’s revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.58) EPS. On average, equities analysts expect that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

PHR has been the subject of several analyst reports. Robert W. Baird dropped their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $24.00 to $32.00 in a report on Wednesday. JMP Securities reiterated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Finally, KeyCorp upped their price objective on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $30.64.

Institutional Investors Weigh In On Phreesia

Large investors have recently added to or reduced their stakes in the business. Trust Point Inc. boosted its position in Phreesia by 3.5% in the 3rd quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock valued at $408,000 after buying an additional 607 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Phreesia by 3.2% in the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock valued at $477,000 after acquiring an additional 700 shares in the last quarter. Rhumbline Advisers boosted its holdings in Phreesia by 1.0% in the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock valued at $1,741,000 after purchasing an additional 853 shares during the period. The Manufacturers Life Insurance Company grew its stake in Phreesia by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock worth $637,000 after purchasing an additional 905 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Phreesia by 3.8% during the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock worth $701,000 after purchasing an additional 1,120 shares during the period. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.